Principal Financial Group Inc. Has $82.21 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Principal Financial Group Inc. cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 129,625 shares of the biopharmaceutical company's stock after selling 865 shares during the period. Principal Financial Group Inc. owned about 0.12% of Regeneron Pharmaceuticals worth $82,212,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in REGN. Pinney & Scofield Inc. acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its position in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the period. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the period. Finally, Tompkins Financial Corp acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $545.00 on Friday. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company's fifty day moving average price is $549.38 and its two-hundred day moving average price is $625.94. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a market cap of $58.84 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 2.00 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the company posted $9.55 EPS. The business's quarterly revenue was down 3.7% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research report on Monday, June 2nd. Bank of America dropped their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Finally, Robert W. Baird dropped their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $822.58.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.